Article
Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Blood advances - 11 Jul 2023
Griffin Rosalie, Wiedmeier-Nutor Julia E, Parikh Sameer A, McCabe Chantal E, O'Brien Daniel R, Boddicker Nicholas J, Kleinstern Geffen, Rabe Kari G, Bruins Laura, Brown Sochilt, Bonolo de Campos Cecilia, Ding Wei, Leis Jose F, Hampel Paul J, Call Timothy G, Van Dyke Daniel L, Kay Neil E, Cerhan James R, Yan Huihuang, Slager Susan L, Braggio Esteban
Abstract excerpt
TP53 aberrations, including mutations and deletion of 17p13, are important adverse prognostic markers in chronic lymphocytic leukemia (CLL) but are less studied in high count monoclonal B-cell lymphocytosis (HCMBL), an asymptomatic pre-malignant stage of CLL. Here we estimated the prevalence and impact of TP53 aberrations in 1,230 newly diagnosed treatment-naïve individuals (849 CLL, 381 HCMBL). We defined TP53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.